Tanezumab

BIOLOGICAL18 trials

Sponsors

Pfizer, Massachusetts General Hospital

Conditions

ArthritisBone MetastasisCancer PainChronic Low Back PainChronic PancreatitisChronic Prostatitis With Chronic Pelvic Pain SyndromeCystitis, InterstitialDiabetic Peripheral Neuropathy

Phase 1

Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

CompletedNCT00788294

PfizerHealthy Volunteers

Start: 2008-11-30End: 2009-06-30Updated: 2020-10-06

Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

CompletedNCT01030640

PfizerChronic Low Back Pain, Osteoarthritis Pain, Pain Due to Interstitial Cystitis

Start: 2009-12-31End: 2010-09-30Updated: 2011-04-26

Phase 2

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

TerminatedNCT00784693

PfizerEndometriosis

Start: 2008-12-18End: 2010-04-05Updated: 2021-04-30

An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis

CompletedNCT00826514

PfizerChronic Prostatitis With Chronic Pelvic Pain Syndrome

Start: 2009-03-25End: 2010-03-17Updated: 2021-05-13

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

TerminatedNCT00999518

PfizerCystitis, Interstitial

Start: 2010-01-22End: 2011-01-21Updated: 2021-08-03

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

TerminatedNCT01087203

PfizerDiabetic Peripheral Neuropathy

Start: 2010-03-30End: 2011-07-06Updated: 2021-02-24

Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

TerminatedNCT01146561

PfizerChronic Pancreatitis

Start: 2010-10-13End: 2011-03-22Updated: 2021-03-23

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Active, not recruitingNCT04163419

Massachusetts General HospitalPain, Schwannomatosis

Start: 2020-04-30End: 2024-09-30Updated: 2024-03-13

Phase 3

Tanezumab in Osteoarthritis of the Knee

CompletedNCT00733902

PfizerArthritis, Osteoarthritis

Start: 2008-09-15End: 2010-01-14Updated: 2021-03-22

Tanezumab in Osteoarthritis Of The Hip

CompletedNCT00744471

PfizerArthritis, Osteoarthritis, Osteoarthritis, Hip

Start: 2008-11-17End: 2010-08-13Updated: 2021-02-26

Extension Study Of Tanezumab In Osteoarthritis

TerminatedNCT00809783

PfizerOsteoarthritis

Start: 2009-02-06End: 2011-06-23Updated: 2021-05-10

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

TerminatedNCT00809354

PfizerArthritis, Osteoarthritis

Start: 2009-02-12End: 2011-01-12Updated: 2021-06-24

Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip

TerminatedNCT00864097

PfizerOsteoarthritis

Start: 2009-08-11End: 2010-11-24Updated: 2021-02-26

Tanezumab and Nerve Function In Arthritis Patients

TerminatedNCT00863772

PfizerOsteoarthritis

Start: 2009-05-18End: 2010-11-16Updated: 2021-02-04

Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

TerminatedNCT00960804

PfizerOsteoarthritis

Start: 2010-02-15End: 2010-11-11Updated: 2021-02-08

Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis

TerminatedNCT01127893

PfizerOsteoarthritis

Start: 2010-06-15End: 2010-09-29Updated: 2021-03-10

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

CompletedNCT02609828

PfizerBone Metastasis, Cancer Pain

Start: 2015-10-28End: 2021-06-25Updated: 2023-02-16

Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.

CompletedNCT02709486

PfizerOsteoarthritis, Hip, Osteoarthritis, Knee

Start: 2016-03-02End: 2018-11-14Updated: 2019-06-26

Related Papers

Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis

Advances in Rheumatology2024-04-221 citations

Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab

Osteoarthritis and Cartilage2023-08-2921 citations

Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor

CPT Pharmacometrics & Systems Pharmacology2023-07-201 citations

Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.

2023-07-183 citations

A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis

The Oncologist2023-06-2143 citations

Barriers to participation in a prospective clinical trial for schwannomatosis-related pain (P7-13.003)

Neurology2023-04-25

Examining the Relationships Among Treatment, Pain, and Physical Function in Patients With Osteoarthritis

Clinical Journal of Pain2023-02-072 citations

Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials

Clinical Pharmacology & Therapeutics2023-01-0913 citations

A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis.

2022-10-272 citations

Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis.

2022-09-012 citations

Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.

2022-08-262 citations

Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials

Current Medical Research and Opinion2022-08-186 citations

Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis.

2022-08-12

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab.

2022-07-022 citations

Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.

2022-05-102 citations

WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee

The Journal of Rheumatology2022-03-0123 citations

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis.

2022-02-012 citations

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials

International Journal of Clinical Practice2021-10-093 citations

Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis.

2021-10-042 citations

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

European Journal of Pain2021-03-1710 citations

9 more papers not shown